Aqua Bio Technology ASA (ABT.OL)
NOK 6.93
(0.0%)
NOK 6.93
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2021 | - NOK | 0.0% |
| 2020 | - NOK | 0.0% |
| 2019 | - NOK | 0.0% |
| 2018 | - NOK | -100.0% |
| 2017 | 666.66 Thousand NOK | -50.0% |
| 2016 | 1.33 Million NOK | -35.48% |
| 2015 | 2.06 Million NOK | -22.49% |
| 2014 | 2.66 Million NOK | -55.56% |
| 2013 | 6 Million NOK | -11.76% |
| 2012 | 6.8 Million NOK | 0.0% |
| 2011 | - NOK | -100.0% |
| 2010 | 7.37 Million NOK | 71.69% |
| 2009 | 4.29 Million NOK | 43.2% |
| 2008 | 3 Million NOK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 Q2 | - NOK | 0.0% |
| 2021 Q2 | - NOK | 0.0% |
| 2021 FY | - NOK | 0.0% |
| 2021 Q4 | - NOK | 0.0% |
| 2020 FY | - NOK | 0.0% |
| 2020 Q4 | - NOK | 0.0% |
| 2020 Q2 | - NOK | 0.0% |
| 2019 Q2 | - NOK | 0.0% |
| 2019 Q4 | - NOK | 0.0% |
| 2019 FY | - NOK | 0.0% |
| 2018 Q2 | 500 Thousand NOK | 0.0% |
| 2018 Q4 | - NOK | 0.0% |
| 2018 FY | - NOK | -100.0% |
| 2017 Q2 | 1 Million NOK | 0.0% |
| 2017 FY | 666.66 Thousand NOK | -50.0% |
| 2017 Q4 | 666.66 Thousand NOK | 0.0% |
| 2016 Q2 | 5.26 Million NOK | 6.75% |
| 2016 Q1 | 4.93 Million NOK | 138.79% |
| 2016 Q4 | 1.33 Million NOK | -74.69% |
| 2016 FY | 1.33 Million NOK | -35.48% |
| 2016 Q3 | 5.26 Million NOK | 0.0% |
| 2015 Q3 | 5.33 Million NOK | 1.27% |
| 2015 FY | 2.06 Million NOK | -22.49% |
| 2015 Q2 | 5.26 Million NOK | -5.78% |
| 2015 Q1 | 5.59 Million NOK | 109.7% |
| 2015 Q4 | 2.06 Million NOK | -61.26% |
| 2014 FY | 2.66 Million NOK | -55.56% |
| 2014 Q4 | 2.66 Million NOK | -62.62% |
| 2014 Q3 | 7.13 Million NOK | -6.55% |
| 2014 Q2 | 7.63 Million NOK | -9.84% |
| 2014 Q1 | 8.46 Million NOK | 41.1% |
| 2013 Q3 | 9.22 Million NOK | -2.12% |
| 2013 FY | 6 Million NOK | -11.76% |
| 2013 Q4 | 6 Million NOK | -34.98% |
| 2013 Q1 | 9.62 Million NOK | 41.59% |
| 2013 Q2 | 9.42 Million NOK | -2.08% |
| 2012 FY | 6.8 Million NOK | 0.0% |
| 2012 Q4 | 6.8 Million NOK | -3.95% |
| 2012 Q3 | 7.08 Million NOK | 0.0% |
| 2012 Q2 | 7.08 Million NOK | 129.87% |
| 2012 Q1 | 3.08 Million NOK | 0.0% |
| 2011 FY | - NOK | -100.0% |
| 2011 Q2 | 6.53 Million NOK | -7.69% |
| 2011 Q4 | - NOK | -100.0% |
| 2011 Q3 | 6.46 Million NOK | -1.1% |
| 2011 Q1 | 7.07 Million NOK | -4.07% |
| 2010 FY | 7.37 Million NOK | 71.69% |
| 2010 Q4 | 7.37 Million NOK | 0.0% |
| 2009 FY | 4.29 Million NOK | 43.2% |
| 2008 FY | 3 Million NOK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Arctic Bioscience AS | 2.04 Million NOK | 100.0% |
| ArcticZymes Technologies ASA | 8.41 Million NOK | 100.0% |
| BerGenBio ASA | - NOK | NaN% |
| Hofseth BioCare ASA | 97.1 Million NOK | 100.0% |
| PCI Biotech Holding ASA | - NOK | NaN% |
| Thor Medical ASA | - NOK | NaN% |
| Ultimovacs ASA | 1.88 Million NOK | 100.0% |